We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Encysive Pharmaceuticals has announced interim results from its ongoing study, STRIDE-2X, evaluating Thelin (sitaxsentan sodium) and bosentan in patients with pulmonary arterial hypertension.
Results of a randomized, multicenter, double-blind parallel group dose ranging study of an advanced formulation of high-strength mesalamine, SPD476, were presented at the World Congress of Gastroenterology in Montreal, Canada.
Data from a XLHealth clinical trial demonstrates that adding daily supplementation with Diachrome to prescription treatment regimens can significantly improve glycemic control in poorly controlled blood sugar levels in people with Type 2 diabetes.
A Phase Ib clinical trial testing the Novogen cardiovascular investigational drug trans NV-04 has been completed at the Baker Heart Research Institute in Melbourne, Australia.
CuraGen and TopoTarget have initiated patient dosing in a Phase Ib open-label, multicenter, proof-of-concept clinical trial evaluating PXD101, a small molecule histone deacetylase inhibitor, for the treatment of advanced solid tumors, including ovarian cancer.
CardioVascular BioTherapeutics has announced that their investigational new drug application to the FDA has been allowed and the company is now authorized to commence its Phase I clinical trial in diabetic patients who have foot ulcers and/or open leg wounds.
Pro-Pharmaceuticals announced that it has submitted a clinical protocol for a Phase II study of its lead carbohydrate compound Davanat with chemotherapeutic agent 5-Fluorouracil for first line treatment of patients with cholangiocarcinoma (cancer of the bile duct).
An independent data safety monitoring board (DSMB) has reviewed a planned interim safety analysis of Tanox's Phase II clinical trial of TNX-355 for treatment of HIV and has recommended continuation of the trial.